Merrimack Pharmaceuticals (MACK) PT Raised to $15 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Merrimack Pharmaceuticals (MACK) Weakness Creates Buying Opportunity, Mizuho Securities Says
October 23, 2015 6:51 AM EDTWeakness in Merrimack Pharmaceuticals (NASDAQ: MACK) following FDA approval of ONIVYDE presents a buying opportunity, according to Eric Criscuolo of Mizuho Securities. The firm reiterated an Outperform rating and price target of $16.
Criscuolo commented, "We think the 13% decline following news of ONIVYDE approval... More
